Entasis Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Entasis Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH2466459D
  • |
  • Pages: 30
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company's pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. Entasis' ETX0914, is an oral antibiotic for the treatment of uncomplicated gonorrhoea. The company's pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.

Entasis Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11

Entasis Therapeutics Raises USD50 Million in Series B Financing 13

Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 14

Partnerships 15

Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 15

Licensing Agreements 16

Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 16

Entasis Therapeutics Inc - Key Competitors 17

Entasis Therapeutics Inc - Key Employees 18

Entasis Therapeutics Inc - Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Corporate Communications 20

May 01, 2018: Entasis Therapeutics Appoints David C. Hastings to Board of Directors 20

Apr 10, 2017: Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer 21

Product News 22

06/30/2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 22

06/07/2017: Entasis Therapeutics Presents Data on ETX2514 at ASM Microbe 2017 23

05/22/2017: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2017 24

05/22/2017: Entasis Therapeutics to Present Data on ETX1317 at ASM Microbe 2017 25

05/22/2017: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2017 26

Clinical Trials 27

Oct 09, 2017: Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017, Announces Plans to Advance Combination with sulbactam (ETX2514SUL) into Phase 2 Trials 27

Sep 28, 2017: Entasis Therapeutics to Present Phase 1 Data on ETX2514 at IDWeek 2017 28

Apr 21, 2017: Entasis Therapeutics to Present Data on ETX2514SUL at 27th European Congress of Clinical Microbiology and Infectious Diseases 29

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30

List of Figures

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Entasis Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Entasis Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11

Entasis Therapeutics Raises USD50 Million in Series B Financing 13

Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 14

Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 15

Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 16

Entasis Therapeutics Inc, Key Competitors 17

Entasis Therapeutics Inc, Key Employees 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Entasis Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18445
Site License
USD 500 INR 36890
Corporate User License
USD 750 INR 55335

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com